180 related articles for article (PubMed ID: 22893871)
1. Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?
Kim TW; Kim HJ; Chon CU; Won HS; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
Clin Mol Hepatol; 2012 Jun; 18(2):203-12. PubMed ID: 22893871
[TBL] [Abstract][Full Text] [Related]
2. Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States.
Wijarnpreecha K; Li F; Xiang Y; Xu X; Zhu C; Maroufy V; Wang Q; Tao W; Dang Y; Pham HA; Zhou Y; Li J; Zhang X; Xu H; Taner CB; Yang L; Tao C
Aliment Pharmacol Ther; 2021 Aug; 54(4):481-492. PubMed ID: 34224163
[TBL] [Abstract][Full Text] [Related]
3. The use of β-blockers is associated with a lower risk of developing hepatocellular carcinoma in patients with cirrhosis.
Herrera I; Pascual S; Zapater P; Carnicer F; Bellot P; María Palazón J
Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1194-7. PubMed ID: 27294486
[TBL] [Abstract][Full Text] [Related]
4. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.
Scheiner B; Parada-Rodriguez D; Bucsics T; Schwabl P; Mandorfer M; Pfisterer N; Riedl F; Sieghart W; Ferlitsch A; Trauner M; Peck-Radosavljevic M; Reiberger T
Scand J Gastroenterol; 2017 Sep; 52(9):1008-1015. PubMed ID: 28532189
[TBL] [Abstract][Full Text] [Related]
5. Effect of Nonselective β-Blockers on Mortality in Patients With End-Stage Cirrhosis.
Snoga JL; Lusk KA; Attridge RT; Attridge RL
Ann Pharmacother; 2020 Apr; 54(4):322-330. PubMed ID: 31701773
[No Abstract] [Full Text] [Related]
6. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.
Mandorfer M; Bota S; Schwabl P; Bucsics T; Pfisterer N; Kruzik M; Hagmann M; Blacky A; Ferlitsch A; Sieghart W; Trauner M; Peck-Radosavljevic M; Reiberger T
Gastroenterology; 2014 Jun; 146(7):1680-90.e1. PubMed ID: 24631577
[TBL] [Abstract][Full Text] [Related]
7. Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites.
Onali S; Kalafateli M; Majumdar A; Westbrook R; O'Beirne J; Leandro G; Patch D; Tsochatzis EA
Liver Int; 2017 Sep; 37(9):1334-1344. PubMed ID: 28296047
[TBL] [Abstract][Full Text] [Related]
8. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.
Bossen L; Krag A; Vilstrup H; Watson H; Jepsen P
Hepatology; 2016 Jun; 63(6):1968-76. PubMed ID: 26599983
[TBL] [Abstract][Full Text] [Related]
9. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.
Sersté T; Melot C; Francoz C; Durand F; Rautou PE; Valla D; Moreau R; Lebrec D
Hepatology; 2010 Sep; 52(3):1017-22. PubMed ID: 20583214
[TBL] [Abstract][Full Text] [Related]
10. Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis.
Kim BH; Chung JW; Lee CS; Jang ES; Jeong SH; Kim N; Kim JW
Korean J Intern Med; 2019 Nov; 34(6):1233-1243. PubMed ID: 30759966
[TBL] [Abstract][Full Text] [Related]
11. Non-selective beta-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD ≥ 12 over 5 years of follow-up.
Calès P; Bertrais S; Boursier J; Fouchard I; Oberti F;
Liver Int; 2021 Jan; 41(1):168-179. PubMed ID: 32979020
[TBL] [Abstract][Full Text] [Related]
12. Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation.
Ngwa T; Orman E; Gomez EV; Vuppalanchi R; Kubal C; Chalasani N; Ghabril M
BMC Gastroenterol; 2020 Jan; 20(1):4. PubMed ID: 31906860
[TBL] [Abstract][Full Text] [Related]
13. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers.
Shukla R; Kramer J; Cao Y; Ying J; Tansel A; Walder A; Advani S; El-Serag HB; Kanwal F
Am J Gastroenterol; 2016 Dec; 111(12):1778-1787. PubMed ID: 27670600
[TBL] [Abstract][Full Text] [Related]
14. Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation.
Cheng HY; Lin HC; Lin HL; Uang YS; Keller JJ; Wang LH
Front Pharmacol; 2021; 12():805318. PubMed ID: 35069216
[No Abstract] [Full Text] [Related]
15. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study.
Kang SH; Lee M; Kim MY; Lee JH; Jun BG; Kim TS; Choi DH; Suk KT; Kim YD; Cheon GJ; Kim DJ; Baik SK
Hepatol Int; 2021 Apr; 15(2):424-436. PubMed ID: 33860898
[TBL] [Abstract][Full Text] [Related]
16. The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis.
Sersté T; Njimi H; Degré D; Deltenre P; Schreiber J; Lepida A; Trépo E; Gustot T; Moreno C
Liver Int; 2015 Aug; 35(8):1974-82. PubMed ID: 25611961
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
Fernández Carrillo C; Lens S; Llop E; Pascasio JM; Crespo J; Arenas J; Fernández I; Baliellas C; Carrión JA; de la Mata M; Buti M; Castells L; Albillos A; Romero M; Turnes J; Pons C; Moreno-Planas JM; Moreno-Palomares JJ; Fernández-Rodriguez C; García-Samaniego J; Prieto M; Fernández Bermejo M; Salmerón J; Badia E; Salcedo M; Herrero JI; Granados R; Blé M; Mariño Z; Calleja JL
Hepatology; 2017 Jun; 65(6):1810-1822. PubMed ID: 28170112
[TBL] [Abstract][Full Text] [Related]
18. Changes in Characteristics of Patients with Liver Cirrhosis Visiting a Tertiary Hospital over 15 Years: a Retrospective Multi-Center Study in Korea.
Jang WY; Chung WJ; Jang BK; Hwang JS; Lee HJ; Hwang MJ; Kweon YO; Tak WY; Park SY; Lee SH; Lee CH; Kim BS; Kim SH; Suh JI; Park JG
J Korean Med Sci; 2020 Jul; 35(29):e233. PubMed ID: 32715667
[TBL] [Abstract][Full Text] [Related]
19. Nonselective beta-blockers may lead to stage 2 acute kidney injury and waitlist mortality in child class C cirrhosis.
Lai M; Fenton C; Ge J; Rubin J; Lai JC; Cullaro G
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37756037
[TBL] [Abstract][Full Text] [Related]
20. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials.
Thiele M; Albillos A; Abazi R; Wiest R; Gluud LL; Krag A
Liver Int; 2015 Aug; 35(8):2009-16. PubMed ID: 25581713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
